3 completed, 1 recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow MLDL1278A: new trials by email Literature Review of MLDL1278A trials Research Report on MLDL1278A
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Focused Orticumab Research for Treating Inflammation in Coronary Arteries Orticumab, Placebo - Acute Coronary Syndromes, Coronary Arterial Disease (CAD) | Phase 2 | Recruiting | Abcentra | 240 | 2025-08-11 | 2026-01-27 |
| A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors Orticumab, Placebo - Psoriasis, Inflammation | Phase 2 | Completed | Abcentra | 77 | 2021-06-30 | 2026-05-11 |
| Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects MLDL1278A - Healthy | Phase 1 | Completed | BioInvent International AB | 22 | 2011-11-01 | 2012-12-11 |
| A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER) MLDL1278A, placebo, statin, stable dose - Atherosclerosis | Phase 2 | Completed | Genentech, Inc. | 147 | 2010-03-01 | 2016-11-02 |
Inflammation (2) · Acute Coronary Syndrome (1) · Atherosclerosis (1) · Coronary Artery Disease (1) · Heart Diseases (1) · Metabolic Syndrome (1) · Myocardial Infarction (1) · Psoriasis (1)
Abcentra (2) · BioInvent International AB (1) · Genentech, Inc. (1)
United States (3) · United Kingdom (2) · Canada (1) · Czechia (1) · Hungary (1) · Italy (1) · Poland (1) · Romania (1) · Spain (1) · Sweden (1)
Darren Wilbraham, MD (1) · Joel Neutel, MD (1) · Joshua Lehrer-Graiwer, M.D. (1)